论文部分内容阅读
目的探讨血栓通粉针联合尼莫地平治疗早期脑梗死的临床疗效并探讨其对血清超敏C-反应蛋白(high sensitivity C-Reactive Protein,hs-CRP)的影响。方法将符合入选标准的102例早期脑梗死患者随机分为联合治疗组和对照组,均为51例。在一般治疗基础上,治疗组应用血栓通粉针联合尼莫地平治疗,对照组患者应用尼莫地平治疗,疗程均为14d。两组治疗前后均进行神经功能缺损评分及血清hs-CRP水平测定。结果联合治疗组总有效率(92.2%)明显高于对照组(76.5%)(P<0.05)。14d时,治疗组血清hs-CRP水平较对照组明显降低(P<0.05)。结论血栓通粉针联合尼莫地平治疗早期脑梗死的临床疗效确切,并可降低脑梗死患者血清hs-CRP水平,减轻血管炎性反应,值得临床推广。
Objective To investigate the clinical efficacy of thrombosis combined with nimodipine in the treatment of early cerebral infarction and its effect on serum high sensitivity C-reactive protein (hs-CRP). Methods A total of 102 patients with early cerebral infarction who met the inclusion criteria were randomly divided into combined treatment group and control group, 51 cases in each group. On the basis of general treatment, the treatment group was treated with thrombosis combined with nimodipine, and the control group was treated with nimodipine for 14 days. Neurological deficit scores and serum hs-CRP levels were measured before and after treatment in both groups. Results The total effective rate (92.2%) in the combined treatment group was significantly higher than that in the control group (76.5%) (P <0.05). On the 14th day, the hs-CRP level in the treatment group was significantly lower than that in the control group (P <0.05). Conclusion Thrombosis powder injection combined with nimodipine in the treatment of early cerebral infarction clinical efficacy and can reduce serum hs-CRP levels in patients with cerebral infarction, reduce vascular inflammatory response, is worth clinical promotion.